Pentetate Zinc Trisodium

CHEMBL1200424 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
522.7 g/mol
LogP
Phase
4

A zinc-containing DTPA chelating agent used to treat internal contamination with plutonium, americium, and curium, particularly when given after the first 24 hours when calcium DTPA becomes less effective. It promotes renal excretion of radioactive heavy metals.

Molekularmasse

522,7000 g/mol

TPSA

210,00 Ų

Therapeutische Bereiche

Wirkmechanismus

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CCN(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Na+].[Zn+2]

InChI

InChI=1S/C14H23N3O10.3Na.Zn/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;;;;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);;;;/q;3*+1;+2/p-5

Molecular Formula

C14H18N3Na3O10Zn

HBD / HBA

- / 13

Rotierbare Bindungen

11

Schwere Atome

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A zinc-containing DTPA chelating agent used to treat internal contamination with plutonium, americium, and curium, particularly when given after the first 24 hours when calcium DTPA becomes less effective. It promotes renal excretion of radioactive heavy metals.

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Yes, Pentetate Zinc Trisodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200424. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 164209. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.